51
BIBLIOGRAFIA
[1] Kiessling, M.; Gauss, P. Stimulus-trascription coupling in focal cerebral ischemia. Brain Pathol. 4(1), 77-83, 1994.
[2] Macdermott, A.B., M.L. Mayer, G.L. Westbrook. NMDA receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurons. Nature 321. 519-522. 1986.
[3] Alderton, W.K., Cooper, C.E. and Knowles. Biochem. J. 357. 593–615. 2001. [4] Li, H.; Poulos, T.L. Structures-fuction studies on nitric oxide synthases. J.Inorg.Biochem. 99(1). 293-305. 2005.
[5] Murphy, S. and Pearce, B.R. in Neuroglia, 2nd edn (Kettenmann,H. and Ransom, B.R., eds). 216–228, Oxford University Press, NewYork. 2005.
[6] Dawson, V.L. Mechanisms of NO-medicated neurotoxicity in primary brain cultures. J. Neurosci. 13. 2651-2661. 1993.
[7] Moncada, S. & A. Higgs. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329. 2002–2012. 1993.
[8] Jaffery, S.R. & S.H. Snyder. Nitric oxide: a neural messenger. Ann. Rev. Cell.Dev. Biol. 11. 417–440. 1995.
[9] Beckman, J., J. Chen, J. Crow & Y. Ye. Reactions of nitric oxide, superoxide and peroxynitrite with SOD in neurodegeneration. Prog. Brain Res. 103. 371– 380. 1994.
[10] Schulz JB, Lindenau J, Seyfried J et al.Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 267(16). 4904–4911. 2000.
[11] Slemmer, J.E.; Sweeney, M.I. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. Curr Med Chem. 15(4). 404-14. 2008.
[12] Murphy, S. and Coughlan. Neurochemistry and molecular neurobiology. 3rd end (Lajtha, A., ed). 223-247. 2006.
[13] Valko, M.; Leibfritz, D. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 39 (1). 44-84. 2007.
52 [14] Harman D. Aging. A teory based on free radical and radiation chemistry. J. Gerontol. 11. 298-300. 1956.
[15] Selkoe HG, Perry G. Phosphorylation in Alzheimer’s disease: pathogen or protector? Trends Mol. Med. 11. 164-169. 2005.
[16] Teter B. ApoE-dependent plasticity in Alzheimer’s disease. J. Mol. Neurosci. 23. 167-179. 2004.
[17] Javitch, J.A. Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U.S.A. 82. 2173–2177. 1985.
[18] Yelin, R. & S. Schuldiner. The pharmacological profile of the vesicular monoamine transporter resembles that of multidrug transporters. FEBS Lett. 377. 201–217. 1995.
[19] Greenamyre, J.T. Mitochondrial dysfunction in Parkinson’s disease. Biochem. Soc. Symp. 66. 85–97. 1999.
[20] Mohanakumar K. P & D. Muralikrishnan. Neurochemical mechanisms underlying neuroprotective actions of bromocriptine, salicylate, D- and L-deprenyl in neurodegeneration caused by MPTP. In Neurotoxic Factors in Parkinson’s Disease and Related Disorders. M.A. Collins & A. Storch. 289–293. 2000.
[21] Dykens, J.A. Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated Ca2+ and Na+: implications for neurodegeneration. J. Neurochem. 63. 584–591. 1994.
[22] Alderton, W.K., Cooper, C.E. and Knowles. Biochem. J. 357. 593–615. 2001. [23] Willmot, M., Gray. Nitrix Oxide. 12. 141-149. 2005.
[24] Furfine, E. S.; Harmon, M. F.; Selective inhibition of constitutive nitric oxide synthase by L-N-nitroarginina. Biochemistry. 32. 8512-8517. 1993.
[25] Yamamoto, K.; Shimamura, K. Effects of N-nitro-L-arginine on the blood pressure of spontaneously hypertensive rats with different degrees of hypertension. Clin. Exp. Hypertens. 23 (7). 533-544. 2001.
53 [26] Huang, H.; Martasek, P. Syntheses and evaluation of dipeptide amides containing N-nitroarginine and D-2,4-diaminobutyric acid as inhibitors of neuronal nitric oxide synthase. J. Enzyme Inhib. 16. 233-239. 2001.
[27] Griffith, O.W. & D.J. Stuehr. Nitric oxide synthase: properties and catalytic mechanism. Annu. Rev. Physiol. 57. 707–736. 1995.
[28] Garthwaite, G. & J. Garthwaite. NO does not mediate glutamate neurotoxicity, nor is it neuroprotective, in rat brain slices. Neuropharmacology 33. 1431–1438. 1994.
[29] Stamler, J.S. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 78. 931–936. 1994.
[30] Lipton, S.A. & J.S. Stamler. Actions of redox-related congeners of nitric oxide at the NMDA receptor. Neuropharmacology. 33. 1229–1233. 1994.
[31] Lipton , S.A. Neuronal protection and descruction by NO. Cell Death Differ. 6. 943-951 . 1999 .
[32] Lipton , S.A. Neuronal protection and descruction by NO. Cell Death Differ. 6. 943-951 . 1999 .
[33] Ontèniente, B ;Couriaud. The mechanisms of cell death in focal cerebral ischemia higlihght neuroprotective perpectives by anti-caspase therapy. Biochem Pharmacol. 66(8).1643-9. 2003.
[34] Kruidering , M.& G . I. Evan. Caspase-8 in apoptostis: the beginning of the and? IUBMB Life. 50 . 85-90. 2000.
[35] Willmot, M; Gipson . Free Radical . Biol . Med . 39.402-425 . 2005.
[36] Fiorucci, S. NO-releasing NSAIDs are caspase inhibitors. Trends Immunol. 22. 232-235. 2001.
[37] Khaldi, A., A. Zauner. Measurement of nitric oxide and brain tissue oxygen tension in patiens after severe subarachnoid hemorrhage. Neurosurgery. 49. 33-40- 2001.
[38] Iadecola, C. Bright and dark sides of nitric oxide in ischemic brain injury. Trend. Neurosci. 20. 132-139. 1993.
